[Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma].
From January 1990 to November 1994, 23 patients with advanced pretreated lung carcinoma were enrolled into a phase II trial to test a new nitrosourea, cystemustine, given every 2 weeks at the dose of 60 mg/m(2) in a 15-minute IV infusion. All eligible patients were considered evaluable for response and toxicity (WHO criteria).
Rebattu
P
P
Centre Léon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France.
Coudert
B
B
Schneider
M
M
Ouabdesselam
R
R
Lentz
M
M
Hanauske
A
A
Chevallierdagger
B
B
Fumoleau
P
P
Chollet
P
P
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009607:Nitrosourea Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D010166:Palliative Care
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C051263:N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea